// App-Quantinova.ai

TPS178 : A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).

Researchers

Presenter

  • Karim Fizazi

Principal Investigators

  • Daniel J. George

  • Maria De Santis

  • Noel Clarke

  • Andre P. Fay

  • Hirotsugu Uemura

  • Lynda Grinsted

  • Claire Rooney

  • Remy B Verheijen

  • Rana Anjum

  • Andrew Foxley

  • Thomas Morris

Medical Centers

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC

  • LBI-ACR Vienna, Kaiser Franz Josef Hospital, Center for Oncology and Hematology, Vienna, Austria

  • The Christie and Salford Royal NHS Foundation Trusts, Manchester, United Kingdom

  • PUCRS School of Medicine, Porto Alegre, Brazil

  • Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan

  • AstraZeneca Oncology Innovative Medicines, Macclesfield, United Kingdom

  • Johnson & Johnson, South Holland, Netherlands

  • AstraZeneca, Waltham, MA

  • Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom

  • AstraZeneca, Macclesfield, United Kingdom

Locations

  • France

  • United States

  • Austria

  • United Kingdom

  • Brazil

  • Japan

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Phosphatase and tensin homolog

Drug/Treatment

  • CB-7598

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03072238

  • NCT04493853

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved